Equities analysts predict that Seres Therapeutics Inc (NASDAQ:MCRB) will announce sales of $6.69 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Seres Therapeutics’ earnings. The lowest sales estimate is $3.00 million and the highest is $9.26 million. Seres Therapeutics posted sales of $9.06 million during the same quarter last year, which would indicate a negative year over year growth rate of 26.2%. The business is scheduled to issue its next earnings report on Thursday, November 14th.
On average, analysts expect that Seres Therapeutics will report full-year sales of $31.96 million for the current year, with estimates ranging from $22.32 million to $38.37 million. For the next year, analysts forecast that the company will post sales of $39.68 million, with estimates ranging from $18.70 million to $56.50 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.17. The business had revenue of $12.53 million during the quarter, compared to the consensus estimate of $10.29 million.
In other news, Director Noubar Afeyan acquired 8,888,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was acquired at an average price of $2.25 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director now directly owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 37.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of MCRB. Tower Research Capital LLC TRC lifted its position in Seres Therapeutics by 3,656.7% during the second quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 8,447 shares during the period. BNP Paribas Arbitrage SA lifted its position in Seres Therapeutics by 945.5% during the first quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,924 shares during the period. SG Americas Securities LLC bought a new stake in Seres Therapeutics during the second quarter worth about $34,000. Parametric Portfolio Associates LLC bought a new stake in Seres Therapeutics during the second quarter worth about $42,000. Finally, A.R.T. Advisors LLC bought a new stake in Seres Therapeutics during the second quarter worth about $64,000.
Shares of Seres Therapeutics stock traded up $0.34 during trading on Wednesday, reaching $3.31. The company’s stock had a trading volume of 277,229 shares, compared to its average volume of 414,186. The business’s 50-day moving average price is $2.85 and its 200-day moving average price is $4.70. The firm has a market cap of $199.25 million, a PE ratio of -1.36 and a beta of 2.03. Seres Therapeutics has a 52 week low of $2.02 and a 52 week high of $9.26.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Recommended Story: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.